Q2 2026 delivered 15% revenue growth, strong operating leverage, and a narrowed net loss, driven by broad-based demand and expanding physician adoption. Guidance was raised, with multiple catalysts ahead, including a new product launch and favorable reimbursement changes.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.